CHARACTERISTICS OF CEREBRAL TOXLOPLASMOSIS IN HIV PATIENTS: RETROSPECTIVE ANALYSIS OF 135 CASES IN DNIPROPETROVSK REGION

Authors

  • L. R. Shostakovych-Koretska 1ДЗ «Дніпропетровська медична академія МОЗ України»,
  • K. Yu. Lytvyn 1ДЗ «Дніпропетровська медична академія МОЗ України»,
  • O. О. Volikova 1ДЗ «Дніпропетровська медична академія МОЗ України»,
  • О. О. Bilokon 1ДЗ «Дніпропетровська медична академія МОЗ України»,
  • І. P. Mishkoy 2КЗ «Дніпропетровський обласний центр з профілактики та боротьби зі СНІДом»
  • Z. О. Chykarenko 1ДЗ «Дніпропетровська медична академія МОЗ України»,
  • O. A. Kushnierova 1ДЗ «Дніпропетровська медична академія МОЗ України»,
  • S. A. Halushchenko 1ДЗ «Дніпропетровська медична академія МОЗ України»,

DOI:

https://doi.org/10.11603/2415-8798.2017.4.8404

Keywords:

HIV infection, cerebral toxoplasmosis, co-infection, central nervous system (CNS ).

Abstract

From 40 to 70 % of patients with HIV have neurological disorders. Toxoplasmosis is one of the most common causes of brain damage in patients with HIV, which often leads to mortality.

The aim of the study – to determine and compare the main characteristics of the central nervous system toxoplasmosis in HIV-positive patients who had different outcome of the disease (survived or died as a result of the disease).

Materials and Methods. A retrospective cohort analysis of 135 cases of cerebral toxoplasmosis in HIV-positive patients in the Dnipropetrovsk region (Ukraine) from 2010 to 2017 was conducted. The presence of toxoplasmosis was confirmed by the detection of DNA of Toxoplasma gondii in the cerebrospinal fluid, and in the dead patients, the study of autopsy material was performed. Statistical processing of the results of the study was conducted using STAT IST ICA v.6.1® and SPSS programs. In order to compare the indicators in the groups of patients who died and those who survived, odds ratios (OR s) were calculated with confidence intervals (95 % CI).

Results and Discussion. Toxoplasmosis was diagnosed in 30 % of HIV-positive patients with CNS disordrers. Most of the patients were males – 71 (52.6 %), the average age was 37.79±0.64. The number of fatal cases was 29 (21.5 %). The groups of patients who survived or died did not differ significantly in age ((37.47±0.72) versus (38.93±1.46) years)) (p>0.05) and gender composition (male 53.8 % vs. 48.3 % of women). Sexually transmitted infections occurred in 40.0 % of cases, because of injecting drug use (IDU s) – 34.8 %, the infection route was uncertain in 25.2 %. In the dead, the uncertain route of infection was 51.7 % versus 17.9 % (p<0.001) of surviving patients. In 43 patients (31.9 %) with cerebral toxoplasmosis, the HIV status was determined in the same year or at the same time as the development of toxoplasmosis. The frequency of late detection of HIV (less than a year before the manifestation of CNS toxoplasmosis) in patients who died was 6.49 times higher (95 % CI 2.64–15.95) compared survivors. 76 (56.3 %) of patients had CD4 levels of less than 50 cells/mm3, including those in deaths, this figure was 1.5 times higher – 75.9 % vs. 50.9 % (p<0.05) in survivors. Median CD4 in the period of development of neurological diseases in patients with toxoplasmosis of the central nervous system was 44.5 (IQR 21–100) cells/mm3, of which in patients who died – 33 (IQR 15–44) cells/mm3 vs. 52 (IQR 25–106) cells/mm3 in survivors (p<0.05). The median of viral load (lg VL ) in the period of development of neurological symptoms was 4.96 (IQR 1.60–5.80) copies/ml, and in patients who died, it was 6.20 (IQR 6.05–6.31) copies/ml and significantly exceeded the same rate in those who were discharged with improvement status – 4.89 (IQR 1.60–5.72) copies/ml (p<0.05). Among clinical symptoms, the most common in patients with toxoplasmosis of the central nervous system were: headache – 86 (63.7 %) patients, dizziness and coordination disorders – 81 (60.0 %), convulsions 43 (31.9 %), mono- and hemiparesis – 57 (42.2 %), disorders of cranial nerves – 37 (27.4 %), dysarthria – 27 (20.0 %), cognitive impairment – 29 (21.5 %), disturbed consciousness – 14 (10.4 % ), visual impairment – 7 (5.2 %) cases. In 30 (22.2 %) patients there was a combination of toxoplasmosis and other diseases of the central nervous system. The development of co-infection of toxoplasmosis with tuberculosis in patients with fatal outcome of the disease was observed 4.5 times more often (95 % CI 1.42–14.29) than in survivors (p<0.05). The spread of Epstein-Barr viral infection among the deceased was 4.21 times higher (95 % CI 1.11–15.90) (p<0.05).

Conclusions. Cerebral toxoplasmosis accounts for 30.0 % of all HIV-associated infectious disorders of the central nervous system in patients in Dnipropetrovsk region; in 56.3 % of patients, toxoplasmosis is diagnosed at the background of severe immunosuppression, in 21.5 % the primary diagnosed toxoplasmosis has lethal outcome. The chances of lethal outcome of the disease do not depend on gender, age, but significantly increase in the absence of ART , the number of CD4 cells/mm3 less than 50 and the presence of coinfections of the central nervous system, the most important of which is the risk of tuberculosis of the central nervous system. The obtained results are important for predicting the course of the disease and identifying possible risks, for the improvement of preventive measures.

Author Biographies

L. R. Shostakovych-Koretska, 1ДЗ «Дніпропетровська медична академія МОЗ України»,

професор, д. мед. н., завідувач кафедрою інфекційних хвороб ДЗ «ДМА МОЗ України» 

K. Yu. Lytvyn, 1ДЗ «Дніпропетровська медична академія МОЗ України»,

доцент, к. мед. н., доцент кафедри інфекційних хвороб ДЗ «ДМА МОЗ України»,  тел. 0677390951.

Конфлікт інтересів: відсутній.

 

O. О. Volikova, 1ДЗ «Дніпропетровська медична академія МОЗ України»,

асистент кафедри інфекційних хвороб ДЗ «ДМА МОЗ України»

О. О. Bilokon, 1ДЗ «Дніпропетровська медична академія МОЗ України»,

клінічний ординатор кафедри інфекційних хвороб ДЗ «ДМА МОЗ України»

І. P. Mishkoy, 2КЗ «Дніпропетровський обласний центр з профілактики та боротьби зі СНІДом»

лікар-інфекціоніст, КЗ «Дніпропетровського обласного центру з профілактики та боротьби зі СНІДом»

Z. О. Chykarenko, 1ДЗ «Дніпропетровська медична академія МОЗ України»,

доцент, к. мед. н., доцент кафедри інфекційних хвороб ДЗ «ДМА МОЗ України»

O. A. Kushnierova, 1ДЗ «Дніпропетровська медична академія МОЗ України»,

асистент кафедри інфекційних хвороб ДЗ «ДМА МОЗ України»

S. A. Halushchenko, 1ДЗ «Дніпропетровська медична академія МОЗ України»,

доцент, к. мед. н., асистент кафедри інфекційних хвороб ДЗ «ДМА МОЗ України»

References

Bilgrami, M., & O'Keefe, P. (2014). Neurologic diseases in HIV-infected patients. Handbook of clinical neurology, 121, 1321-1344.

Vivithanaporn, P., Heo, G., Gamble, J., Krentz, H. B., Hoke, A., Gill, M. J., & Power, C. (2010). Neurologic disease burden in treated HIV/AIDS predicts survival: а population-based study. Neurology, 75(13), 1150-1158.

Bolokadze, N., Gabunia, P., Ezugbaia, M., Gatserelia, L., & Khechiashvili, G. (2008). Neurological complications in patients with HIV/AIDS. Georgian medical news, (165), 34-38.

Portegies, P., & Berger, J. R. (2007). HIV/AIDS and the nervous system. Handbook of clinical neurology, 85, 1-2.

Tan, I. L., Smith, B. R., von Geldern, G., Mateen, F. J., & McArthur, J. C. (2012). HIV-associated opportunistic infections of the CNS. The Lancet Neurology, 11(7), 605-617.

Siddiqi, O. K., Ghebremichael, M., Dang, X., Atadzhanov, M., Kaonga, P., Khoury, M. N., & Koralnik, I. J. (2014). Molecular diagnosis of central nervous system opportunistic infections in HIV-infected Zambian adults. Clinical Infectious Diseases, 58(12), 1771-1777.

Abgrall, S., Rabaud, C., Costagliola, D., & Clinical Epidemiology Group of the French Hospital Database on HIV. (2001). Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clinical Infectious Diseases, 33(10), 1747-1755.

Sacktor, N. (2002). The epidemiology of human immunodeficiency virus–associated neurological disease in the era of highly active antiretroviral therapy. Journal of neurovirology, 8.

Shostakovych-Koretska L.R., Lytvyn K.Yu., Hubar I.O., Volikova O.O., Chykarenko Z.О., Kushnierova O.A., Sheveliova O.V. (2017). Analiz zmin syrovatkovoho beta-2-mikrohlobulinu ta pokaznykiv hematolohichnoho profiliu u patsiientiv iz VIL-asotsiiovanymy nevroloholichnymy zakhvoriuvanniamy [Analysis of changes of serum beta-2-microglobulin and hematological parameters in patients with HIV-associated neurological diseases]. Visnyk naukovykh doslidzhen – Bulletin of scientific research, 3, 110-113 [in Ukrainian].

Shostakovych-Koretska L.R., Volikova O.O., Lytvyn K.Yu., Hubar I.O., Kushnierova O.A., Sheveliova O.V. (2017). HLA DRB1 polimorfizm ta ryzyk vynyknennia ko-infektsii VIL/tuberkuloz [HLA DRB1 polymorphism and risk of HIV/tuberculosis co-infection]. Medychni perspektyvy – Medical perspectives, ХХІІ(3), 81-88 [in Ukrainian].

Shostakovych-Koretska L.R., Lytvyn K.Yu., Volikova O.O., Hubar I.O., Suremenko M.S., Kushnierova O.A., Sheveliova O.V. (2017). Riven syrovatkovoho beta-2-mikrohlobulinu ta yoho zviazok z imunolohichnymy ta hematolohichnymy pokaznykamy pry prohresuvanni VIL [Serum levels of β-2-microglobulin and its relationship to immunological and hematological parameters in the progression of HIV-infection]. Infektsiini khvoroby – Infectious diseases, 3(89), 18-23. [in Ukrainian]

Berhe, T., Melkamu, Y., & Amare, A. (2012). The pattern and predictors of mortality of HIV/AIDS patients with neurologic manifestation in Ethiopia: a retrospective study. AIDS research and therapy, 9(1), 11.

Dai, L., Mahajan, S. D., Guo, C., Zhang, T., Wang, W., Li, T., ... & Li, N. (2014). Spectrum of central nervous system disorders in hospitalized HIV/AIDS patients (2009–2011) at a major HIV/AIDS referral center in Beijing, China. Journal of the neurological sciences, 342(1), 88-92.

Jowi JO, Mativo PM, Musoke SS. Clinical and laboratory characteristics of hospitalised patients with neurological manifestations of HIV/AIDS at the Nairobi hospital. East Afr Med J 2007;84:67-76.

Richards Jr, F. O., Kovacs, J. A., & Luft, B. J. (1995). Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Clinical infectious diseases,21(Supplement_1), S49-S56.

Israelski, D. M., Chmiel, J. S., Poggensee, L., Phair, J. P., & Remington, J. S. (1993). Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. JAIDS Journal of Acquired Immune Deficiency Syndromes, 6(4), 414-418.

Nissapatorn, V., Lee, C., Quek, K. F., Leong, C. L., Mahmud, R., & Abdullah, K. A. (2004). Toxoplasmosis in HIV/AIDS patients: a current situation. Japanese journal of infectious diseases, 57(4), 160-165.

Luft, B. J., Hafner, R., Korzun, A. H., Leport, C., Antoniskis, D., Bosler, E. M., ... & Morlat, P. (1993). Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine, 329(14), 995-1000.

Published

2018-01-13

How to Cite

Shostakovych-Koretska, L. R., Lytvyn, K. Y., Volikova O. О., Bilokon О. О., Mishkoy І. P., Chykarenko Z. О., … Halushchenko, S. A. (2018). CHARACTERISTICS OF CEREBRAL TOXLOPLASMOSIS IN HIV PATIENTS: RETROSPECTIVE ANALYSIS OF 135 CASES IN DNIPROPETROVSK REGION. Bulletin of Scientific Research, (4). https://doi.org/10.11603/2415-8798.2017.4.8404

Issue

Section

NEUROLOGY AND PSYCHIATRY